Help:Contents
To be made: Style pages for
- chemotherapy regimens
- diseases
- clinical trials
For the same regimen, but different diseases, will use disambiguation pages directing toward disease-specific pages. This will be instead of putting the disease in parentheses after every regimen to increase simplicity.
How to cite a source:
- Place this information where you want the numeric citation to appear:
<ref>Put the link [http://webaddress.org "text for the link"] inside the ref tags</ref> - Make sure to put <references/> in the reference area at the bottom of the page.
class="wikitable sortable" border="1" style="text-align:center;"
Categories - use for regimens, perhaps for chemotherapies, drug classes
Sample column formatting
|
|
Template to be used for chemotherapies: (strive for minimalism, focus on regimens)
General information
Class/mechanism: Causes damage or degradation of PML-RAR alpha fusion protein, causes apoptosis-type changes in NB4 human promyelocytic leukemia cells in vitro[1][2]
Route: IV
Extravasation: irritant or no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Arsenic trioxide (Trisenox) patient drug information (Chemocare)[3]
- Arsenic trioxide (Trisenox) patient drug information (UpToDate)[4]